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httpcense.Abstract Background: Rapid and accurate diagnosis and management can be lifesaving for
patients with acute dyspnea. However, making a differential diagnosis and selecting early treatment
for patients with acute dyspnea in the emergency setting are a clinical challenge that requires com-
plex decision-making in order to achieve hemodynamic balance, decrease unnecessary usage of anti-
biotic therapy, and decrease mortality.
Aim: To study the efﬁcacy ofmeasuring high sensitivity C-reactive protein (Hs-CRP) and procalc-
itonin (PCT) levels on admission in differentiating acute decompensated heart failure (ADHF) from
community acquired pneumonia (CAP) in patients with acute dyspnea in the emergency setting.
Methods: A comparative analytical study of ADHF included CAP patients admitted to the emer-
gency room for acute dyspnea. Patients who qualiﬁed the criteria for both pneumonia and heart fail-
ure were excluded. Efﬁcacy for Hs-CRP and PCT as a diagnostic markers was evaluated by using
receiver operator curves (ROC).
Results: Thirty patients with ADHF and 30 patients with CAP were studied. Patients with pneu-
monia had increasedHs-CRP and PCT levels on admission (mean values were 76.6 ± 41.8 mg/L, and
0.95 ± 0.54 ng/ml, respectively), compared with those with heart failure (18.53 ± 18.49 mg/L, and
0.09 ± 0.03 ng/ml, respectively). For differentiating pneumonia from HF, the cutoff value of Hs-
CRP was 15 mg/L, with sensitivity 96.7% and speciﬁcity 70%, while the cutoff value of PCT was
0.2 ng/ml with sensitivity 93.3% and speciﬁcity 100%.3939861.
(H.H. Assal).
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456 M.A.H. Abdel Aziz et al.Conclusion: Procalcitonin and Hs-CRP levels can both independently distinguish CAP from
ADHF in the emergency setting.
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Acute dyspnea is one of the most common causes of emergency
department (ED) admission. It is also the main symptom for
which patients with acute decompensated heart failure (ADHF)
require treatment. The early evaluation of acute shortness of
breath poses a diagnostic challenge for the physician, and the
timely differentiation frompotential causes of dyspneamay per-
mit the implementation of appropriate medical therapy.
ADHF has emerged as a major public health problem over
the past 2 decades [1]. Heart failure is the leading cause of hos-
pitalization in patients older than 65 years of age. HF resulting
in hospitalization represents a signiﬁcant and growing health
care burden. In-hospital mortality is excessive and readmission
is disturbingly common, despite advances in pharmacotherapy
and device therapy for HF [2,3].
Suspected community-acquired pneumonia (CAP) is de-
ﬁned as an acute illness with cough and at least one of new fo-
cal chest signs, fever more than 4 days or dyspnea/tachypnea,
and with-out other obvious causes [4].
Deﬁnite community-acquired pneumonia (CAP) is the
same but supported by chest radiograph ﬁndings of lung shad-
owing that is likely to be new [4].
Differentiating the cause of shortness of breath in patients
with cardiac and pulmonary diseases is a big dilemma as many
of these patients present with dyspnea, mild fever and leukocy-
tosis and upon auscultation, there are evident crakles, so history
and physical examination are poor to differentiate. An accurate
diagnosis of ADHF is difﬁcult, especially in elderly or obese pa-
tients given the frequency of comorbidities such as asthma,
chronic obstructive pulmonary disease (COPD), anemia, acido-
sis, and neurologic disorders with a lack of speciﬁcity or sensi-
tivity to the signs and symptoms of heart failure [5].
Electrocardiographic changes are non-speciﬁc to diagnose
decompensated heart failure. Chest radiograph is also non-speciﬁc
as bedside ﬁlms cannot assess cardiac size and the interpretation of
chest roentgenograms is variable, even among radiologists [6,7].
Echocardiography is the gold standard method for detect-
ing left ventricular dysfunction, but it is not often usually
available in emergency care and its performance or interpreta-
tion requires great skill and knowledge by the operator [8].
All these can either mask or mimic a concomitant pneumo-
nia. An erroneous diagnosis of pneumonia can generate several
undesirable results in treatment, diagnostic workout, iatrogenic
complications, prognosis, and misuse of health resources [9,10].
The identiﬁcation of biomarkers such as procalcitonin
(PCT) and High sensitivity C-reactive protein (Hs-CRP) for
the early presentation can guide treatment, reduce misuse of
antibiotics and possibly improve long term outcomes.
C-reactive protein (CRP) is a pentameric protein comprised
of ﬁve identical units. Several functions have been attributed to
C-reactive protein: CRP is capable of binding various biolog-
ical substrates; it participates in the activation of the comple-
ment system and modulates the function of phagocyticleukocytes. CRP is also located at sites of inﬂammation; it en-
hances macrophage action on tumors; it is implicated in the
synthesis of interleukine-1 (IL-1) and tumor necrosis factor
(TNF), and is capable of binding and blocking platelet activat-
ing factor. CRP is mainly produced in the liver in response to
interleukine-6 (IL-6) [11,12].
Elevated levels of CRP have been observed in patients with
heart failure, and activation of the immune response may play
a role in heart failure through modiﬁcations in the renin-angio-
tensin-aldosterone system (RAAS) and sympathetic system
[13]. It is also found that higher CRP levels are related to progres-
sive myocardial functional deterioration independent of subclin-
ical atherosclerosis and clinical coronary events in asymptomatic
individuals without previous history of heart disease [14].
Procalcitonin is 116 amino acid prohormone of the hormone
calcitonin. Calcitonin is exclusively produced by c-cells of the
thyroid gland in response to hormonal stimuli, whereas procalc-
itonin can be produced by several other cell types from a wide
range of organs in response to inﬂammation or infection [15].
Plasma procalcitonin has a half life of 25–30 h. Levels typ-
ically increase within 3–6 h of the stimulus and higher levels
are associated with poorer prognosis. Elevated values are
highly suggestive of an infection, typically bacteria, with a sys-
temic response (sepsis, or severe sepsis or septic shock) [16,17].
Aim of the study
1. To determine the usefulness of serum procalcitonin and Hs
C-reactive protein to differentiate patients with community
acquired pneumonia from acute decompensated heart
failure.
2. To identify the values of procalcitonin and Hs C-reactive
protein above which we can diagnose community acquired
pneumonia.Patients and methods
We initially recruited 76 patients admitted toEDatCairo univer-
sity hospital with shortness of breath between June 2010 and
June 2012. During the study, patients who qualiﬁed the criteria
for both pneumonia and heart failure were excluded from the
analysis because including these patients would have distorted
the cutoff values for the diagnosis of either condition alone.
So this study enrolled 60 patients admitted to ED with
acute dyspnea including acute decompensated heart failure
and community acquired pneumonia.
Inclusion criteria
1. Patients with acute respiratory distress within 1 week.
2. Patients with or without underlying history of heart or lung
disease.
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1. Patients with evidence of myocardial infarction within
2 weeks.
2. Patients with chronic inﬂammatory disease such as those
with arthritis, because of the impact of the inﬂammatory
conditions on the level of the CRP.
3. Women on hormone replacement therapy have been shown
to have elevated Hs-CRP levels.
4. Patients with systemic steroid treatment, and anti-inﬂam-
matory drugs, because they reduce Hs-CRP in blood as
they help to reduce the inﬂammation.
5. Pregnant women have been shown to have elevated Hs-
CRP levels.
6. Patients with cardiogenic shock because it causes a pyrexia
of unknown origin in patients surviving for 12 h and that is
associated with a rise in procalcitonin levels [18].
*These patients were classiﬁed according to their diagnosis
into two groups:
Group (A): Includes 30 cases with acute decompensated
heart failure based on the Framingham criteria in which the
diagnosis of heart failure requires the simultaneous presence
of at least two major criteria or one major criterion in conjunc-
tion with two minor criteria [19].
Group (B): Includes 30 cases with deﬁnite community ac-
quired pneumonia [4].
All patients were subjected to:
1. History taking.
2. Clinical examination.
3. Chest radiograph: for assessment of cardiac size and iden-
tiﬁcation of alveolar and interstitial inﬁltration.
Echocardiography study
Standard transthoracic M-mode, two dimensional echocardio-
grams were obtained to assess:
A. LV systolic function: which required
1. Left ventricular end diastolic diameter (LVED): which was
measured from the leading edge of left septal surface to the
leading interface of the left ventricular (LV) endocardium.
2. Left ventricular end systolic diameter (LVES): which was mea-
sured at the peak downwardmotion of inter ventricular septum
to upward motion of the posterior left ventricular wall.
3. Diastolic function: diastolic dysfunction refers to a condi-
tion in which abnormalities in mechanical function are
present during diastole. Pulsed wave Doppler of trans-
mitral ﬂow was used to assess global diastolic function
(sample volume placed at tip of mitral leaﬂet in the apical
4 chamber view), and measure E-wave velocity (E), A
wave velocity, E-wave deceleration time and E/A ratio
[20].
4. Ejection fraction (EF%) was calculated from modiﬁed
Simpson method. The LV endocardial border is traced
from one apical or two orthogonal apical views to create
multiple (usually 20) cylinders whose volume is summated
to provide LV volume and ejection fraction [21].
B. For measurement of pulmonary artery systolic pressure
(PASP), applying the modiﬁed Bernoulli equation using RightVentricular Systolic Pressure which was estimated by measur-
ing the peak Tricuspid Regurgitation jet velocity by Continu-
ous Wave Doppler [22].
General laboratory investigations:
Total leukocytic count (TLC).
Erythrocyte sedimentation rate (ESR).
Sputum culture and sensitivity.
Speciﬁc laboratory investigations:
 Serum Hs-CRP level.
 Serum PCT level.High sensitivity enzyme immunoassay for the quantitative
determination of C-reactive protein concentration in human
serum
Principle of the assay
The principle of a solid phase enzyme-linked immunosorbent
assay (ELISA) of Hs-CRP is based on that CRP molecules
in the sample are sandwiched between two antibodies. The
concentration of CRP is directly proportional the color inten-
sity of the test sample.
Assay procedure
1. Serum samples were frozen at 20 C, then they were cen-
trifuged and diluted 100 fold prior to use.
2. UndilutedCRP standards, diluted specimens and diluted con-
trols were dispensed into appropriate wells to be incubated
and washed every step after addition of CRP Enzyme Conju-
gate Reagent and tetramethylbenzidine (TMB) reagent.
3. The reaction was stopped by adding stop solution and the
absorbance was read after the change of the color from blue
to yellow.Human procalcitonin, PCT ELISA kit
Test principle
Procalcitonin present in the sample is bound to the immobi-
lized antibody speciﬁc for it. The color develops in proportion
to the amount of procalcitonin bound after the addition of the
TMB reagent. The intensity of the color is measured after the
change of the color from blue to yellow by the stop solution.
Assay procedure
1. Standard and sample were added into the appropriate wells
to be incubated and washed every step after addition of bio-
tinylated antibody, Streptavidin solution, and TMB reagent.
2. The reaction was stopped by adding stop solution and the
absorbance was read.
Statistical analysis
The obtained data of every patient were collected in a separate
patient sheet then tabulated in a master table and fed to the
computer on SPSS version 17, statistical program for analysis
of data.
Table 2 Gender distribution in the studied groups.
HF CAP p Value
Number % Number %
Male 17 56.70 18 60 0.79
Female 13 43.30 12 40
Table 3 Smoking distribution in the two groups.
HF CAP p Value
Number % Number %
Smoking 11 36.70 14 47 0.43
Table 4 Comparison between the mean systolic blood
pressure (SBP) and diastolic blood pressure (DBP) of the two
study groups.
HF CAP p Value
Mean ±SD Mean ±SD
SBP 148.5 ±21.6 131.5 ±15.4 0.001*
DBP 97 ±9.8 87.2 ±10.2 <0.001*
* P < 0.01 signiﬁcant.
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Parametric and non-parametric t test compared means of
independent groups.
Chi-square and/ﬁsher exact were used to test proportion
independence.
ROC receiver operator characteristic curve was used to se-
lect a cut-off point for procalcitonin and Hs-CRP.
Validity measures were sensitivity and speciﬁcity.
Correlations between variables were tested by the Pearson
rank correlation test (r= correlation coefﬁcient).
p Value was considered signiﬁcant 60.05.
Results
The current comparative analytical study included 60 patients
admitted to ED with shortness of breath; 30 patients with
heart failure (group A) and 30 patients with community ac-
quired pneumonia (group B). (Tables 1–7)
Comparison between the two study groups as regards diastolic
dysfunction
All patients (100%) in group A had diastolic dysfunction,
while 18 patients (60%) in group B had diastolic dysfunction,
with statistically signiﬁcant p value (p 6 0.001). (Table 8)
Comparison of PCT and Hs-CRP according to the sputum
culture
Twenty patients (33.3%) had positive sputum cultures in both
groups: Klebsiella, n= 7 (11.7%); Streptococcus pneumonia,
n= 3 (5%); Staphylococcus aureus, n= 2 (3.3%); Candida,
n= 3 (5%); MRSA, n= 1 (1.7%); Klebsiella+ S. aureus,
n= 1 (1.7%); Klebsiella+ Escherichia coli, n= 1 (1.7%);
Klebsiella+ Acinetobacter, n= 2 (3.3%).
Patients with positive sputum cultures had higher levels of
PCT and Hs-CRP, with statistically signiﬁcant p value
(p= 0.000). (Table 9)
Correlations between Hs-CRP level and age, NYHA (New York
Heart Association) class, EF%, and PCT level in group A
 There was a positive correlation between Hs-CRP level and
NYHA class (r= 0.67), (p= 0.000).
 There was a negative correlation between Hs-CRP level and
EF% (r= 0.92), (p= 0.000).
 There was a negative correlation between NYHA class and
EF% (r= 0.77), (p = 0.000).Table 1 Comparison between the mean ages of the two
groups.
HF CAP p Value
Mean ±SD Mean ±SD
Age 63.6 ±7.8 54.1 ±17.9 0.01*
* P < 0.01 signiﬁcant. There was no correlation between Hs-CRP level and PCT
level (r= 0.003), (p= 0.98).
 There was no correlation between Hs-CRP level and age
(r= 0.22), (p= 0.23).
Correlations between Hs-CRP level and age, EF%, and PCT
level in group B
- There was a positive correlation between Hs-CRP level and
PCT level (r= 0.64), (p= 0.000). (Fig 1)
- There was no correlation between Hs-CRP level and EF%
(r= 0.27), (p= 0.15).
- There was no correlation between Hs-CRP level and age
(r= 0.00), (p= 0.99).
Sensitivity and speciﬁcity of procalcitonin to discriminate HF
from CAP(ﬁg. 2)
PCT can be used to diagnose acutely dyspnic patients with
heart failure or Community acquired pneumonia: a PCT
>0.2 ng/ml deﬁned community-acquired pneumonia and a
PCT <0.2 ng/mL deﬁned heart failure with sensitivity 93.3%
and speciﬁcity 100%. (Table 10)
Sensitivity and speciﬁcity of Hs-CRP to discriminate HF from
CAP(Fig. 3)
Hs-CRP can be used to diagnose acutely dyspnic patients with
heart failure or Community acquired pneumonia: a Hs-CRP
Table 5 Comparison between group A and group B as regards Fever, PND, Cough, Dyspnea, APE (acute pulmonary edema),
Pulmonary rales, Raised JVP(jugular venous pressure), S3, Hepatomegaly, Hepatojugular reﬂux, L.L.(lower limb) edema, Weight loss,
History of chest infection, and Statin use.
HF CAP p Value
Number % Number %
Fever 3 10 26 86.7 <0.001*
P.N.D. 24 80 0 0 <0.001*
Cough 5 16.7 19 63.3 <0.001*
Dyspnea 30 100 30 100 N.S.
APE 17 56.7 0 0 <0.001*
Pulmonary rales 27 90 22 73 0.3
Raised JVP 25 83.3 1 3.3 <0.001*
S3 12 40 0 0 <0.001*
Hepatomegaly 24 80 6 20 <0.001*
Hepatojugular reﬂux 6 20 0 0 0.01*
L.L.edema 22 73.3 2 6.7 <0.001*
Weight loss 7 23.3 0 0 0.005*
History of chest infection 1 3.3 26 86.7 <0.001*
Statin use 14 46.7 11 36.7 0.43
* P < 0.01 signiﬁcant.
Table 6 Comparison of radiologic parameters in both study
groups.
HF CAP p Value
Number % Number %
Cardiomegaly 23 76.7 4 13.3 <0.001*
Lung congestion 24 80 0 0 <0.001*
Lung inﬁltrate 6 20 26 86.7 <0.001*
Pleural eﬀusion 10 33.3 6 20 <0.001*
* P < 0.01 signiﬁcant.
Table 7 Comparison of PCT, Hs-CRP, ESR and TLC in both
study groups.
HF CAP p Value
Mean ±SD Mean ±SD
PCT (ng/ml) 0.09 ±0.03 0.95 ±0.54 <0.001*
Hs-CRP (mg/L) 18.53 ±18.49 76.6 ±41.8 <0.001*
ESR 23.17 ±7.63 67.77 ±15.9 <0.001*
TLC (/cm) 7.93 ±2.93 17.9 ±5.22 <0.001*
* P < 0.01 signiﬁcant.
Table 8 Comparison of Echocardiographic parameters in
both groups.
HF CAP p Value
Mean ±SD Mean ±SD
LVED 6.09 ±0.63 5.37 ±0.38 <0.001*
LVES 4.97 ±0.74 3.54 ±0.33 <0.001*
EF 37.13 ±10.89 67.77 ±5.16 <0.001*
PASP 38.7 ±11.85 28.50 ±12.71 0.002*
* P < 0.01 signiﬁcant.
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CRP <15 mg/L deﬁned heart failure with sensitivity 96.7%
and speciﬁcity 70%. (Table 11)
Discussion
Heart failure and community acquired pneumonia are major
health problems in developed countries and are responsible
for a great number of hospitalizations and deaths.
Differentiating the diagnosis of pneumonia from that of HF
in patients presenting with a chief complaint of dyspnea can be
difﬁcult, and disastrous consequences may occur from a mis-
take [23,24] because of the similar and therefore non-speciﬁc
physical exam and chest X-ray abnormalities. It is our impres-
sion that due to the difﬁculty of establishing a diagnosis based
on clinical and radiological ﬁndings alone and due to the grave
consequences of failing to diagnose these patients, misuse of
antibiotics which in turn is associated with adverse reactions,
high cost and the emergence of bacterial resistance [25], another
criteria must be used. In this study, we evaluated serumHs-CRP
and PCT as an aid for the diagnosis of these patients.
C-reactive protein is a sensitive marker for pneumonia, it is
an acute-phase protein synthesized by the liver that is found
only in trace amounts in the plasma of healthy subjects. A rise
in IL-6 after a tissue injury mediates the production of CRP
within hours [26]. Thus, an elevated serum concentration of
CRP is unequivocal evidence of active tissue damage. An in-
creased CRP level has also been reported to be an independent
predictor of heart failure in study of a community-based el-
derly population [27]. It is also found that higher CRP levels
are related to progressive myocardial functional deterioration.
Procalcitonin has recently emerged as a promising alternative
inﬂammatory biomarker. PCT is a peptide precursor of the hor-
mone calcitonin and rises in response to inﬂammatory stimulus.
It has been proposed as a marker of bacterial infection in ill pa-
tients. Use of thismarker panelmay improve the diagnostic accu-
racy over standard clinical judgment of ED physicians.
Figure 2 ROC (receiver operator characteristic curve) of sensi-
tivity and speciﬁcity of Procalcitonin.
Table 10 Sensitivity and speciﬁcity of Procalcitonin to
discriminate HF from CAP.
Procalcitonin HF CAP
Number % Number %
60.21 30 100.00 2 7
>0.21 0 0.00 28 93.3
Figure 3 ROC Curve of sensitivity and speciﬁcity of Hs-CRP.
Table 11 Sensitivity and speciﬁcity of H-s CRP to discrim-
inate HF from CAP.
Hs-CRP HF CAP
Number % Number %
<15 21 70 1 3.3
P15 9 30 29 96.7
Table 9 Comparison of PCT and Hs-CRP according to the
sputum culture.
Positive sputum
culture
Negative sputum
culture
p Value
Mean ±SD Mean ±SD
PCT (ng/ml) 1.17 ±0.49 0.19 ±0.24 0.000*
Hs-CRP (mg/L) 87.54 ±42.43 27.57 ±27.31 0.000*
* P < 0.01 signiﬁcant.
Figure 1 Correlation between Hs-CRP level (mg/L) and procalc-
itonin level (ng/ml) in group B.
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fer substantially in the observed levels of Hs-CRP
(18.53 ± 18.49 vs. 76.6 ± 41.8 mg/L, p< 0.001). Employingan ROC diagram, the admission level of hs-CRP 15 mg/L
was the cutoff value for ruling-in pneumonia with sensitivity
96.7% and speciﬁcity 70%.
The same was reported by Castro-Guardiola et al. who
studied 284 consecutive patients diagnosed in the emergency
ward as having CAP where the diagnosis was reviewed by
the investigators applying pre-set diagnostic criteria. Statistical
analysis was then performed comparing data from patients
with a deﬁnitive diagnosis of CAP (208 patients) with those
with a ﬁnal diagnosis of non-pneumonia disease (76 patients)
to suggest higher cutoff value to be 100 mg/L with sensitivity
70% and speciﬁcity 96% [28].
Also, a similar study by Erel Joffe et al. as 72 patients with
ADHF and 50 patients with pneumonia were included in this
study. The mean CRP levels on admission were 13.5 ±
13.5 mg/L for the ADHF patients and 127 ± 84 mg/L for
the pneumonia patients (p< 0.001), suggested the cutoff value
for ruling-in pneumonia to be 72.5 mg/L [29].
The difference of the cutoff values across different studies
could be explained by the use of different reagents used to
measure CRP e.g. the immunoturbidimetric assay, and auto-
mated latex-enhanced turbidimetric assay.
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had higher serum level of Hs-CRP, had a higher NYHA func-
tional class (r= 0.67) (p= 0.000). It was also proved by Alon-
so-Martinez et al. who studied the relation between 76 patients
with heart failure and CRP (mean 3.9 ± 5.9) by using Nephe-
lometer analyzer and stated that an inﬂammatory response is
present in deteriorating heart failure and observed that higher
CRP levels in patients with higher NYHA functional class,
perhaps signaling a poor therapeutic response and higher
CRP levels were also related to higher rates of readmission
and mortality and it could be an independent marker of
improvement and readmission in heart failure [12].
We observed that the higher the serum level of CRP, the
lower the LVEF (r= 0.92) (p= 0.000). Arroyo-Espliguero
et al. studied 841 patients with chronic stable angina undergo-
ing coronary angiography and the symptoms of CHF were as-
sessed using NYHA functional classiﬁcation. CRP
measurements were performed using a high sensitivity immu-
noassay at the time of diagnostic coronary angiography and
found that Hs-CRP serum concentrations showed an inverse
correlation with LVEF (r= 0.11; p= 0.004) and were an
independent predictor of NYHA functional class in patients
with chronic stable angina [30].
Our results suggest that PCT provides additive diagnostic
information in patients presenting with shortness of breath;
models using PCT were robust when clinical uncertainty ex-
isted. We found the cutoff value for ruling-in pneumonia to
be 0.2 ng/ml with sensitivity 93.3% and speciﬁcity 100%, while
a similar study by Cinar et al. suggested the cutoff value for
ruling-in pneumonia to be 0.25 ng/ml to indicate an infectious
etiology of dyspnea. He enrolled 154 patients with a chief com-
plaint of shortness of breath and uncertain diagnosis in his
study to ﬁnd that PCT had 48.8% sensitivity and a 96.5%
speciﬁcity with cutoff value 0.25 ng/ml [31].
Also, Maisel et al. studied 1641 patients presented to EDs
with dyspnea in which 155 patients had a diagnosis of pneumo-
nia with the median PCT concentration was 0.18 ng/ml, and
for the patients without pneumonia PCT was 0.07 ng/ml [32].
Our results also found that patients with positive sputum
cultures had higher levels of PCT and hs-CRP compared to pa-
tients with negative sputum cultures, with statistically signiﬁ-
cant p value (p= 0.000).
Also, Schuetz et al. found a high diagnostic performance of
PCT with a cutoff of 0.25 ng/ml to exclude bacteremic disease
in patients with CAP, and also found that PCT demonstrated a
better discriminatory ability compared to white blood cells and
CRP to distinguish blood contamination from true blood
stream infection in patients with growth of coagulase-negative
staphylococci in their blood cultures with a cut-off value of
0.1 ng/ml [33].
Conclusion
This study assessed the efﬁcacy of measuring Hs-CRP and pro-
calcitonin levels on admission in differentiating ADHF from
CAP in patients with acute dyspnea in the emergency setting.
Our ﬁndings indicate that patients with pneumonia had in-
creased Hs-CRP and PCT levels on admission compared with
those with heart failure.
The cutoff value for Hs-CRP for differentiating pneumonia
from HF is 15 mg/L.The cutoff value for procalcitonin for differentiating pneu-
monia from HF is 0.2 ng/ml.
Our ﬁndings indicate that the levels of Hs-CRP increase
with the severity of CHF, as we observed that the higher the
serum level of Hs-CRP, the higher NYHA functional class
and the lower LVEF.
According to our ﬁndings, Hs-CRP and procalcitonin mea-
surements may be used since the ﬁrst day of hospitalization for
differentiating community acquired pneumonia patients from
acute decompensated heart failure patients.
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